Trial Profile

A Phase II, Single Arm Study Investigating Neoadjuvant Plus Adjuvant Treatment with Cemiplimab in High Risk, Surgically Resectable, Stage III Cutaneaous Squamous Cell Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2023 Results (n=23; From May 2021 to October 2022) assessing the efficacy and safety of neoadjuvant plus adjuvant cemiplimab in patients with surgically resectable, high-risk stage III/IV cutaneous squamous cell carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
20 Feb 2023 Status changed from recruiting to active, no longer recruiting.
27 Jul 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Oct 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com